- 衛教專區
輝瑞/BioNTech mRNA 疫苗的保護力
（出現症狀且實驗室證實的新冠病毒感染）
- 43,548受試者≥16歲1:1隨機分派接受疫苗或安慰 劑
- Efficacy in prevention of symptomatic Covid19 illness
- Per-protocol 95.0% (95% CI, 90.0% - 97.9%)
- Intention-to-treat 94.8% (95% CI, 89.8% - 97.6%)
- 打完第一劑 52.0%
- 打完第一劑未打第二劑 52.4%
- 打完第二劑的7天之內 90.5%
- 打完第二劑的7天之後 94.8% New Engl J Med 383, 2603–2615 (2020)
莫德那(Moderna) mRNA 疫苗保護力
（出現症狀且實驗室證實的新冠病毒感染）
• 30,420受試者≥18歲1:1隨機分派接受疫苗或安慰劑
• Efficacy in prevention of symptomatic Covid19 illness
• All patients 94.1% (95% CI, 89.3% - 96.9%)
• ≥18 to < 65 yr 95.6% (95% CI, 90.6% - 97.9%)
• ≥ 65 yr 86.4% (95% CI, 61.4% - 95.2%)
• 打完第一劑後14天內 54.4% • 打完第一劑14天至打第二劑前 94.3%
• 打完第二劑的14天之內 100.0%
• 打完第二劑的14天之後 94.1% New Engl J Med 384, 403–416 (2020)
AZ腺病毒載體疫苗的保護力
（出現症狀且實驗室證實的新冠病毒感染）
• 11,636受試者≥18歲1:1隨機分派接受試驗或對照疫苗
• Efficacy in prevention of symptomatic Covid-19 illness
• All recipients 70.4% (95% CI, 54.8% - 80.6%)
• LD/SD recipients (≤55yr) 90.0% (95% CI, 67.4% - 90.0%)
• SD/SD recipients 62.1% (95% CI, 41.0% - 75.7%)
• 18-55 yr-o, >8wks interval
• LD/SD recipients 90.0% (95% CI, 67.3% - 97.0%)
• SD/SD recipients 65.6% (95% CI, 24.5% - 84.4%)
• All SD/SD • <6 wks interval 53.4% (95% CI, -2.5%–78.8%)
• ≥6 wks interval 65.4% (95% CI, 4.1% - 79.6%) Lancet 397, 99–111 (2021)
